Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
Thomas PfeifferIfigeneia TzannouMengfen WuCarlos Almeida RamosGhadir SasaCaridad MartinezPremal D LullaRobert A KranceLauren SchererDaniel RuderferSwati NaikClaire E BocchiniIain P FraserBadrish PatelDany WardNicholas WangHelen E HeslopAnn M LeenBilal OmerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In this open-label trial, treatment of refractory viral infections/disease in allo-HCT recipients with posoleucel was feasible, safe, and effective.